354 related articles for article (PubMed ID: 34359604)
1. Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis.
Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Sagara H
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359604
[TBL] [Abstract][Full Text] [Related]
2. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M; Shao T; Shao H; Zhou C; Tang W
BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
[TBL] [Abstract][Full Text] [Related]
4. Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis.
Filetti M; Lombardi P; Falcone R; Giusti R; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
Explor Target Antitumor Ther; 2023; 4(6):1136-1144. PubMed ID: 38213541
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain.
Presa M; Vicente D; Calles A; Salinas-Ortega L; Naik J; García LF; Soto J
Clinicoecon Outcomes Res; 2023; 15():659-671. PubMed ID: 37701861
[TBL] [Abstract][Full Text] [Related]
6. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials.
Hoang T; Myung SK; Pham TT; Park B
Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32106398
[TBL] [Abstract][Full Text] [Related]
8. Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia-a case report.
Sasaki K; Yokota Y; Isojima T; Fujii M; Hasui K; Chen Y; Saito K; Takahata T; Kindaichi S; Sato A
Respirol Case Rep; 2021 Jul; 9(7):e00796. PubMed ID: 34123384
[TBL] [Abstract][Full Text] [Related]
9. Relationship between Anaplastic Lymphoma Kinase (ALK) Inhibitors and Epileptic Seizure Disorder: A Post-Marketing Surveillance Study.
Noguchi Y; Asano H; Masuda R; Teshigawara Y; Go M; Kimura M; Usami E; Yoshimura T
Oncology; 2024 May; ():. PubMed ID: 38768582
[TBL] [Abstract][Full Text] [Related]
10. Lorlatinib Versus Crizotinib in Patients With Advanced
Solomon BJ; Liu G; Felip E; Mok TSK; Soo RA; Mazieres J; Shaw AT; de Marinis F; Goto Y; Wu YL; Kim DW; Martini JF; Messina R; Paolini J; Polli A; Thomaidou D; Toffalorio F; Bauer TM
J Clin Oncol; 2024 May; ():JCO2400581. PubMed ID: 38819031
[TBL] [Abstract][Full Text] [Related]
11. Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an
Carcereny E; Fernández-Nistal A; López A; Montoto C; Naves A; Segú-Vergés C; Coma M; Jorba G; Oliva B; Mas JM
Oncotarget; 2021 Feb; 12(4):316-332. PubMed ID: 33659043
[TBL] [Abstract][Full Text] [Related]
12. Real world study of safety and efficacy of lorlatinib as second line and beyond in
Biswas B; Ghadyalpatil NS; Patil S; Patel A; Ganguly S; Rathore A; Guleria B; Tarannum CF; Ghosh J; Kondapally MS; Thippeswamy R; Reddy SHP; Roy S
Ecancermedicalscience; 2024; 18():1667. PubMed ID: 38439810
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of
Dagogo-Jack I; Kiedrowski LA; Heist RS; Lin JJ; Meador CB; Krueger EA; Do A; Peterson J; Sequist LV; Gainor JF; Lennerz JK; Digumarthy SR
JTO Clin Res Rep; 2023 Aug; 4(8):100534. PubMed ID: 37533439
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report.
Niu R; Zhang Y; Pang J; Zhou Q; Lei Y; Du Y
Front Oncol; 2024; 14():1341233. PubMed ID: 38344203
[TBL] [Abstract][Full Text] [Related]
15. Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced
Thummalapalli R; Choudhury NJ; Ehrich F; Beardslee T; Brazel D; Zhang SS; Merchant S; Chen MF; Heller G; Ramalingam SS; Ou SI; Mileham KF; Riely GJ
JTO Clin Res Rep; 2023 Aug; 4(8):100546. PubMed ID: 37644967
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire.
Figueiredo A; Rodrigues A; Gaspar C; Felizardo M
Drugs Real World Outcomes; 2023 Dec; 10(4):545-555. PubMed ID: 37787868
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With
Teraoka S; Hayashi H; Goto Y; Nishio M; Sugawara S; Inoue T; Oizumi S; Toyoizumi S; Matsumura M; Messina R; Kato T
JTO Clin Res Rep; 2024 Mar; 5(3):100632. PubMed ID: 38434770
[TBL] [Abstract][Full Text] [Related]
18. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L).
Ozawa Y; Koh Y; Hase T; Chibana K; Kaira K; Okishio K; Ichihara E; Murakami S; Shimokawa M; Yamamoto N
Ther Adv Med Oncol; 2024; 16():17588359231225046. PubMed ID: 38282663
[TBL] [Abstract][Full Text] [Related]
19. Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report.
Fletcher JA; Mullally WJ; Ladwa R; O'Byrne KJ
JTO Clin Res Rep; 2024 Feb; 5(2):100591. PubMed ID: 38357093
[No Abstract] [Full Text] [Related]
20. Clinical efficacy and safety of crizotinib and alectinib in ALK-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy.
Li Z; Zhao J
Am J Transl Res; 2021; 13(11):13108-13116. PubMed ID: 34956530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
